Explore our series on health plan financial trends
Just launched: Trends for government
In the wake of policy and market turbulence, how have US fully-insured health plans fared? Our health plan financial series explores trends in the performance of health plans across their overall, government, and commercial lines of business between 2011 and 2016.
How biopharma companies are bolstering R&D pipeline through deal-making
Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. But when choosing from the three main options open to them—licensing, mergers and acquisitions, and joint ventures—what factors should they examine, and do deal types differ in the ways they accelerate development and deliver long-term value?